SCHEMBL6741094

SCHEMBL6741094

CCCn1ncc2ccc(CCNCC3CC3)cc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.38
HTR2A P28223 3/20 0.38
HTR2C P28335 3/20 0.38
HTR2B P41595 3/20 0.38
KMO O15229 4/20 0.38
QPCT Q16769 1/20 0.37
MCHR1 Q99705 2/20 0.36
MCHR2 Q969V1 1/20 0.36
SIGMAR1 Q99720 1/20 0.35
PTGER3 P43115 1/20 0.35
ADRA1D P25100 1/20 0.34
ADRA1A P35348 1/20 0.34
ADRA1B P35368 1/20 0.34
CACNA1H O95180 2/20 0.34
HTR1A P08908 2/20 0.33
ADRA2A P08913 2/20 0.33
ADRA2B P18089 2/20 0.33
ADRA2C P18825 2/20 0.33
POLB P06746 1/20 0.33
RECQL P46063 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6744654 0.83 QPCT (0.38) BRD4HTR2AHTR2CHTR2BKMO
SCHEMBL6741089 0.80 PTGER3 (0.41) HTR2AKMOSIGMAR1PTGER3ADRA1D
SCHEMBL19159359 0.79 HTR2A (0.45) BRD4HTR2AHTR2CHTR2BKMO
SCHEMBL6741339 0.74 HRH3 (0.50) MCHR1MCHR2SIGMAR1POLBRECQL
SCHEMBL6746000 0.73 HRH3 (0.40) HTR2AHTR2CHTR2BKMOQPCT
SCHEMBL6739781 0.71 KMO (0.56) HTR2AHTR2CHTR2BKMOQPCT
SCHEMBL7253624 0.70 BRD4 (0.42) BRD4HTR2AHTR2CHTR2BKMO
SCHEMBL3099635 0.70 HTR2A (0.71) HTR2AHTR2CHTR2BKMOHTR1A
SCHEMBL6740873 0.69 KMO (0.39) BRD4HTR2AHTR2CHTR2BKMO
SCHEMBL1967603 0.69 NPY5R (0.56) ADRA1DADRA1AADRA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040167158-A1 Heterocyclic compounds for the treatment of migraine NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) 2004-08-26 US disclosed
US-6716837-B1 INDOLE AND INDAZOLE COMPOUNDS NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) 2004-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167158-A1 Heterocyclic compounds for the treatment of migraine SCN7A, CNR2, HTR7 BRD4 363/4885HTR2A 294/4885HTR2C 116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.